These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 27118189

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. PSMA PET/CT for staging and treatment of prostate cancer.
    Hofman M.
    Clin Adv Hematol Oncol; 2019 Jul; 17(7):370-373. PubMed ID: 31449501
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. PSMA-negative prostate cancer and the continued value of choline-PET/CT.
    Alberts I, Sachpekidis C, Fech V, Rominger A, Afshar-Oromieh A.
    Nuklearmedizin; 2020 Feb; 59(1):33-34. PubMed ID: 31766065
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Molecular Imaging in the Evaluation of 6 Doses of Ra-223 in High-Grade Prostate Cancer: Case Report.
    Medina-Ornelas SS, García-Pérez FO.
    Clin Genitourin Cancer; 2017 Feb; 15(1):e159-e164. PubMed ID: 27424257
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
    Hofman MS, Hicks RJ, Maurer T, Eiber M.
    Radiographics; 2018 Feb; 38(1):200-217. PubMed ID: 29320333
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer.
    Meyer AR, Joice GA, Allaf ME, Rowe SP, Gorin MA.
    Curr Opin Urol; 2018 Nov; 28(6):493-498. PubMed ID: 30188333
    [Abstract] [Full Text] [Related]

  • 18. Prostate cancer imaging for primary detection: PSMA-PET/CT vs MRI. All that glitters is not gold.
    Panebianco V.
    Eur Radiol; 2024 Jun; 34(6):4014-4016. PubMed ID: 38165433
    [No Abstract] [Full Text] [Related]

  • 19. New aspects of molecular imaging in prostate cancer.
    Ceci F, Castellucci P, Cerci JJ, Fanti S.
    Methods; 2017 Nov 01; 130():36-41. PubMed ID: 28711565
    [Abstract] [Full Text] [Related]

  • 20. PSMA PET and Radionuclide Therapy in Prostate Cancer.
    Bouchelouche K, Turkbey B, Choyke PL.
    Semin Nucl Med; 2016 Nov 01; 46(6):522-535. PubMed ID: 27825432
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.